Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04005417 · ClinicalTrials.gov registry record
Meta-analysis of Stannous Fluoride Dentifrice and the Effects on Dentine Hypersensitivity
A clinical trial of Dentine Hypersensitivity, sponsored by Procter and Gamble.
- Completed
- Registry status
- 1,036
- Enrollment target
- 1
- Study location
NCT04005417: Completed study of Dentine Hypersensitivity, sponsored by Procter and Gamble.
NCT04005417 is a study of Dentine Hypersensitivity that has completed, run by Procter and Gamble. The registered enrollment target is 1,036 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04005417, a study of Dentine Hypersensitivity, has completed, sponsored by Procter and Gamble.
- COMPLETED
- Registry status
- 1,036 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this 11 study analysis was to compare the effect of bioavailable stannous fluoride (SnF2) on dentine hypersensitivity versus a positive or negative control dentifrice.
Primary Outcome
The Schiff Sensitivity Scale is assessed for each test tooth via an evaporative air challenge. The examiner records the Schiff Index score corresponding to the response to the air challenge. The Schiff Index Sensitivity scale is scored as follows- 0: tooth/subject did not respond to stimulus, 1: tooth/subject responds to stimulus, but does not request discontinuation of stimulus, 2: tooth/subject responds to stimulus and requests discontinuation or moves form stimulus, 3: tooth/subject responds
Conditions Studied
Interventions
- DRUG Stannous fluoride dentifrice
- DRUG Positive control dentifrice
- DRUG Negative control dentifrice
Study Locations (1)
Ohio
- Multiple P&G Investigation Clinical Sites - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,036 participants |
| Start Date | 2018-01-08 |
| Est. Completion | 2018-11-30 |
What the finished NCT04005417 record still lists
NCT04005417 is an observational study that tracks outcomes without assigning an intervention. Its 1,036 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Dentine Hypersensitivity appearing as the primary indexed condition, and to 3 interventions - of which Stannous fluoride dentifrice is the first listed.
NCT04005417 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT04005417 about?
NCT04005417 is a clinical study titled "Meta-analysis of Stannous Fluoride Dentifrice and the Effects on Dentine Hypersensitivity". The aim of this 11 study analysis was to compare the effect of bioavailable stannous fluoride (SnF2) on dentine hypersensitivity versus a positive or negative control dentifrice.
What is the current status of trial NCT04005417?
This trial is currently completed. The enrollment target is 1,036 participants. The study started on 2018-01-08. Estimated completion is 2018-11-30.
What conditions does trial NCT04005417 study?
This clinical trial studies the following conditions: Dentine Hypersensitivity.
What interventions are being tested in trial NCT04005417?
The interventions under investigation include: Stannous fluoride dentifrice (DRUG), Positive control dentifrice (DRUG), Negative control dentifrice (DRUG).
Who is sponsoring clinical trial NCT04005417?
This trial is sponsored by Procter and Gamble, which has 70 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04005417 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05037682 · 1,035 participants · NA
Pain and Opioid Management in Older Adults
- NCT07282600 · 1,035 participants · Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- NCT07345767 · 1,038 participants · NA
Hypknowledge Nationwide Sleep Extension
- NCT05219110 · 1,040 participants · NA
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI